LENZ THERAPEUTICS, INC. Weighted Average Number of Shares Outstanding, Basic and Diluted
LENZ THERAPEUTICS, INC. (LENZ) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 54.01 million shares for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-12.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2022-05-12
- LENZ THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2022-03-31 was 54.01M shares, a 1476.76% increase year-over-year.
- LENZ THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-12-31 was 53.67M shares, a 1473.91% increase year-over-year.
- LENZ THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-09-30 was 52.77M shares, a 1460.26% increase year-over-year.
- LENZ THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-06-30 was 5.09M shares, a 118.38% increase year-over-year.
- LENZ THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2021 was 28.92M shares, a 1166.12% increase from fiscal 2020.
- LENZ THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2020 was 2.28M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2022-03-31 | 54.01M shares 10-Q · filed 2022-05-12 | 53.84M shares derived: average of 2 quarters · filed 2022-05-12 | 53.48M shares derived: average of 3 quarters · filed 2022-05-12 | 41.38M shares derived: average of 4 quarters · filed 2022-05-12 |
| 2021-12-31 | 53.67M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | 53.22M shares derived: average of 2 quarters · filed 2022-03-21 | 37.18M shares derived: average of 3 quarters · filed 2022-03-21 | 28.92M shares 10-K · filed 2022-03-21 |
| 2021-09-30 | 52.77M shares 10-Q · filed 2021-11-10 | 28.93M shares derived: average of 2 quarters · filed 2021-11-10 | 20.67M shares 10-Q · filed 2021-11-10 | 16.17M shares derived: average of 4 quarters · filed 2022-05-12 |
| 2021-06-30 | 5.09M shares 10-Q · filed 2021-08-12 | 4.41M shares 10-Q · filed 2021-08-12 | 3.97M shares derived: average of 3 quarters · filed 2022-05-12 | 3.83M shares derived: average of 4 quarters · filed 2022-05-12 |
| 2021-03-31 | 3.43M shares 10-Q · filed 2022-05-12 | 3.42M shares derived: average of 2 quarters · filed 2022-05-12 | 3.41M shares derived: average of 3 quarters · filed 2022-05-12 | 3.14M shares derived: average of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | 3.41M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | 3.40M shares derived: average of 2 quarters · filed 2022-03-21 | 3.04M shares derived: average of 3 quarters · filed 2022-03-21 | 2.28M shares 10-K · filed 2022-03-21 |
| 2020-09-30 | 3.38M shares 10-Q · filed 2021-11-10 | 2.86M shares derived: average of 2 quarters · filed 2021-11-10 | 1.91M shares 10-Q · filed 2021-11-10 | |
| 2020-06-30 | 2.33M shares 10-Q · filed 2021-08-12 | 1.16M shares 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |